Community-acquired pneumonia: the best candidates for clarithromycin - Authors' reply

Lancet Respir Med. 2024 Apr;12(4):e17. doi: 10.1016/S2213-2600(24)00035-3. Epub 2024 Feb 28.

Authors

Evangelos J Giamarellos-Bourboulis¹, Michael S Niederman²

Affiliations

¹ Fourth Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, 124 62 Athens, Greece; Hellenic Institute for the Study of Sepsis, Athens, Greece. Electronic address: egiamarel@med.uoa.gr.
² Division of Pulmonary and Critical Care Medicine, Weil Cornell Medicine, New York Presbyterian/Weill Cornell Medical Center, New York, NY, USA.

PMID: 38430925
DOI: 10.1016/S2213-2600(24)00035-3

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / therapeutic use
Clarithromycin / therapeutic use
Community-Acquired Infections* / drug therapy
Humans
Pneumonia* / drug therapy

Substances

Clarithromycin
Anti-Bacterial Agents